Alnylam Delivers a Big Q4 Earnings Beat

Alnylam Pharmaceuticals (NASDAQ:ALNY), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share. Revenue of $593.2 million also outpaced the expected $584 million. This quarter's strong performance was generally fueled by effective product commercialization and strategic execution, despite the complexities Alnylam faced in some market segments.

Source: Analysts' estimates for the quarter provided by FactSet.

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases. It has a strong catalog of approved products and a robust pipeline. It focuses on treatments for rare diseases. Collaborations with industry giants such as Regeneron and Novartis support its commercialization and R efforts.

Continue reading

Source Fool.com